Related references
Note: Only part of the references are listed.
Article
Virology
Metin Yigit et al.
Summary: In the 10th month of the pandemic, healthcare workers in Turkey were first vaccinated with the COVID-19 vaccine, and a study in Ankara evaluated the seroconversion rate of the CoronaVac vaccine. The study found that 22.9% of healthcare workers were seronegative, younger participants had higher antibody levels, and female healthcare workers had significantly higher antibody levels compared to males.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Review
Infectious Diseases
Hin Fung Tsang et al.
Summary: The transmission of COVID-19 remains uncontrollable, with increasing numbers of confirmed and death cases reported worldwide. There is currently no specific antiviral treatment for COVID-19, and treatment guidelines vary between countries. However, combination therapies and repurposing FDA-approved drugs show promise in clinical improvement for severe COVID-19 patients. Generating an ecosystem with effective protection, precautions, and preventive measures is crucial in the absence of specific treatment and vaccines for COVID-19.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2021)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.
Article
Infectious Diseases
Yanjun Zhang et al.
Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.
LANCET INFECTIOUS DISEASES
(2021)
Review
Immunology
Malik Sallam
Summary: COVID-19 vaccine acceptance rates are generally high worldwide, but low rates are reported in the Middle East, Russia, Africa, and certain European countries. This could pose a significant challenge in global efforts to control the pandemic. More studies are recommended to address COVID-19 vaccine hesitancy in different regions.
Article
Immunology
Luisa F. Duarte et al.
Summary: Breakthrough infection cases with CoronaVac vaccine were mostly mild and not necessarily related to inadequate vaccine-induced immunity. Moderate to severe cases were mainly observed in adults over 60 with comorbidities. Immune responses varied in breakthrough cases, emphasizing the need for further research on factors influencing post-vaccination symptomatic infections.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Mine Durusu Tanriover et al.
Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Pinja Jalkanen et al.
Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Raju Vaishya et al.
Summary: The study found that 2.63% of healthcare workers contracted SARS-CoV-2 after receiving COVID-19 vaccination, with 76.5% fully vaccinated and 23.5% partially vaccinated. The odds of infection were higher in females due to their greater involvement in patient care. Only two individuals required hospitalization, none needed ICU admission, and there were no deaths.
INDIAN JOURNAL OF MEDICAL RESEARCH
(2021)
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Immunology
Xiao-Ning Li et al.
Summary: The two-dose inactivated SARS-CoV-2 vaccine showed an effectiveness of 59.0% to 70.2% against the Delta variant, with higher efficacy among participants aged 40-59 years and in females compared to males in preventing COVID-19 and moderate diseases.
EMERGING MICROBES & INFECTIONS
(2021)
Review
Allergy
Ahmet Kursat Azkur et al.
Review
Public, Environmental & Occupational Health
Raghuvir Keni et al.
FRONTIERS IN PUBLIC HEALTH
(2020)
Article
Medicine, General & Internal
Maheshi N. Ramasamy et al.
Review
Biochemistry & Molecular Biology
Yetian Dong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2020)
Article
Nursing
Mei-Yu Yeh et al.
APPLIED NURSING RESEARCH
(2018)
